International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Digital Twin Ecosystems for Personalized Oncology: From Virtual Patients to Real-Time Clinical Intelligence

Dr.Harleen Kaur[1],Dr.Sameer Vyas[2],Dr. Pritam Nair[3],Mrs.Kavya Thomas[4],Dr.Neel Shah[5]

[1]Professor,Department of Biochemistry, Yenepoya Medical College, Mangaluru, India.Harleenkaur78@gmail.com

[2]Assistant Professor,Department of Community Medicine, Yenepoya Medical College,Mangaluru, India.Sameervyas34@gmail.com

[3]Associate Professor,Department of Pharmacology, Yenepoya Medical College, Mangaluru, India.Pritamnair67@gmail.com

[4]Assistant Professor,Department of Anatomy, Yenepoya Medical College, Mangaluru, India.Kavya.thomas12@gmail.com

[5]Professor,Department of Neurology, Yenepoya Medical College, Mangaluru, India.Neelshah88@gmail.com

ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular biology, targeted therapeutics, immunotherapy, and precision medicine. The extraordinary biological heterogeneity of tumors, coupled with dynamic interactions among malignant cells, the immune system, and the tumor microenvironment, continues to challenge conventional treatment strategies. Recent advances in artificial intelligence (AI), computational biology, systems medicine, cloud computing, and multimodal biomedical data integration have introduced digital twin ecosystems as a transformative framework for personalized oncology. Unlike conventional digital twins that primarily represent individual virtual patients, digital twin ecosystems integrate interconnected computational models encompassing radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, electronic health records, hospital information systems, and real-time clinical data streams. These intelligent ecosystems continuously synchronize virtual and biological patients, enabling dynamic prediction of disease progression, therapeutic response, toxicity, recurrence, and long-term clinical outcomes. Advances in machine learning, deep learning, multimodal foundation models, graph neural networks, reinforcement learning, agentic AI, generative AI, and cloud-native computing have accelerated development of real-time digital oncology ecosystems capable of supporting diagnosis, molecular characterization, adaptive therapeutics, immunotherapy optimization, radiation planning, surgical decision-making, clinical trial matching, and survivorship care. Despite substantial progress, important challenges remain regarding interoperability, computational scalability, explainability, cybersecurity, ethical governance, regulatory validation, and equitable implementation. This review presents a comprehensive overview of digital twin ecosystems in oncology, emphasizing computational foundations, clinical applications, technological innovations, and future perspectives for real-time intelligent cancer care.[1]

Keywords: Digital twin ecosystems, Precision oncology, Artificial intelligence, Virtual patients, Clinical intelligence, Computational oncology, Machine learning, Multimodal learning, Personalized medicine, Clinical decision support.

Article History

Received: 10 December 2025**; Accepted:** 18 December 2025**; Published:** 28 December 2025

Citation

Kaur H.,(2025). Digital Twin Ecosystems for Personalized Oncology: From Virtual Patients to Real-Time Clinical Intelligence. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 1(5), 67-75.*

DOI: https://doi.org/10.65477/ijerams.v1.i5.09

1. Introduction

Cancer is an extraordinarily complex disease driven by genomic instability, epigenetic regulation, immune dysregulation, metabolic reprogramming, and continuous interactions within the tumor microenvironment. Although advances in molecular diagnostics and targeted therapies have significantly improved patient outcomes, patients with apparently similar histopathological diagnoses frequently demonstrate remarkably different therapeutic responses, recurrence patterns, and survival outcomes. This biological heterogeneity highlights the limitations of traditional population-based treatment strategies while emphasizing the need for individualized computational approaches capable of adapting to each patient's evolving disease.[2]

Modern oncology generates enormous volumes of heterogeneous biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable biosensors, electronic health records, and real-world clinical documentation. While each modality provides valuable information, integrating these continuously expanding datasets into timely clinical decisions has become increasingly difficult using conventional analytical approaches.[3]

Artificial intelligence has emerged as one of the most transformative technologies in precision oncology by enabling automated interpretation of complex biomedical information. More recently, advances in computational modeling have extended beyond isolated predictive algorithms toward continuously evolving digital twin ecosystems capable of integrating multiple clinical systems into unified intelligent healthcare environments.[4]

Rather than representing only a virtual patient, digital twin ecosystems create interconnected computational infrastructures that continuously synchronize patient data, clinical workflows, biomedical knowledge, healthcare resources, and therapeutic decision-making. These ecosystems support real-time clinical intelligence throughout diagnosis, treatment, monitoring, and survivorship while maintaining physician oversight and multidisciplinary collaboration.[5]

2. Evolution of Digital Twin Ecosystems

Digital twin technology originated in aerospace engineering and advanced manufacturing, where virtual replicas of complex physical systems were created to monitor operational performance, predict failures, and optimize maintenance. These computational principles were subsequently adapted to healthcare, enabling simulation of physiological processes, disease progression, and therapeutic interventions through continuously updated virtual patient models.[6]

Early healthcare digital twins primarily focused on cardiovascular disease, diabetes, orthopedic biomechanics, and intensive care medicine. Oncology rapidly emerged as one of the most promising clinical applications because cancer requires continuous integration of anatomical imaging, pathology, molecular biology, genomics, treatment history, and longitudinal patient monitoring.

Recent advances in cloud computing, multimodal artificial intelligence, Internet of Medical Things (IoMT), digital health platforms, and high-performance computational infrastructure have expanded digital twins into comprehensive ecosystems that connect hospitals, laboratories, imaging centers, wearable devices, and clinical information systems into continuously learning healthcare networks.[7]

These digital twin ecosystems represent the next evolution of precision oncology by enabling coordinated computational intelligence across the entire cancer care continuum rather than isolated prediction tasks.

3. Architecture of Digital Twin Ecosystems

Digital twin ecosystems consist of multiple interconnected computational layers that continuously exchange biomedical information to create comprehensive virtual representations of patients, diseases, healthcare processes, and therapeutic interventions.[8]

The first layer acquires multimodal biomedical information from radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable biosensors, medication records, treatment history, and electronic health records. Additional inputs originate from hospital information systems, pharmacy databases, radiation oncology platforms, surgical planning software, and patient-reported outcomes.

The second layer performs multimodal data harmonization through image normalization, molecular standardization, temporal synchronization, natural language processing, feature extraction, and semantic integration of heterogeneous datasets into unified computational representations.

Artificial intelligence engines subsequently process these harmonized datasets using deep learning, transformer architectures, graph neural networks, probabilistic reasoning, and multimodal foundation models capable of generating comprehensive patient-specific biological representations.

Simulation engines model tumor growth, metastatic dissemination, immune interactions, therapeutic response, toxicity, recurrence, and disease evolution. Finally, intelligent visualization platforms provide clinicians with interactive dashboards supporting diagnosis, treatment optimization, longitudinal monitoring, and multidisciplinary clinical decision-making.[9]

4. Artificial Intelligence Driving Digital Twin Ecosystems

Artificial intelligence serves as the computational intelligence underlying digital twin ecosystems by enabling continuous interpretation of heterogeneous biomedical information. Machine learning algorithms identify statistical relationships among clinical variables and patient outcomes, supporting prediction of recurrence, therapeutic response, survival, and treatment-related toxicity across multiple malignancies.[10]

Deep learning substantially expands predictive capability through automated analysis of radiological imaging, histopathological slides, molecular datasets, physiological signals, and longitudinal clinical records. Transformer architectures efficiently integrate multimodal biomedical information, whereas graph neural networks model biological interaction networks involving genes, proteins, signaling pathways, immune responses, and pharmacological targets.

Foundation models further strengthen scalability by learning generalized biomedical representations from massive multimodal datasets that can subsequently be adapted across diverse oncology applications through transfer learning. These complementary artificial intelligence technologies collectively enable digital twin ecosystems to continuously evolve as new clinical information becomes available.[11]

5. Multimodal Data Integration

The effectiveness of digital twin ecosystems depends upon seamless integration of heterogeneous biomedical information into unified computational representations. Cancer cannot be adequately represented through individual biomarkers because disease behavior reflects interactions among molecular biology, imaging, pathology, physiology, immunity, environmental exposures, and longitudinal clinical events.[12]

Radiological imaging contributes anatomical and functional information regarding tumor morphology, vascularity, metabolism, and disease progression. Digital pathology provides microscopic characterization of tissue architecture, cellular differentiation, stromal remodeling, angiogenesis, and immune infiltration. Multi-omics technologies further describe genomic, transcriptomic, proteomic, metabolomic, epigenomic, and immunomic characteristics that collectively determine tumor biology.

Artificial intelligence harmonizes these complementary datasets through multimodal representation learning, enabling continuously updated virtual patients capable of supporting individualized diagnosis, prognostic prediction, therapeutic planning, and long-term disease monitoring across real-time clinical environments.[13]

6. Virtual Patients and Real-Time Synchronization

Virtual patients represent the central component of digital twin ecosystems. Unlike static computational models, virtual patients continuously synchronize with biological patients through ongoing integration of clinical information acquired throughout diagnosis, treatment, follow-up, and survivorship.[14]

Real-time synchronization incorporates sequential imaging examinations, laboratory investigations, pathology reports, genomic sequencing updates, wearable sensor measurements, medication changes, treatment responses, and patient-reported outcomes into adaptive computational models.

Continuous synchronization enables digital twin ecosystems to recognize evolving biological changes, identify early therapeutic resistance, predict disease progression, estimate toxicity, and recommend individualized treatment modifications before clinically significant deterioration occurs.

These adaptive virtual patients therefore function as continuously learning computational companions that evolve alongside the biological patient throughout the entire oncology journey.[15]

7. Digital Twin Ecosystems in Cancer Diagnosis

Accurate diagnosis remains the foundation of effective cancer management, and digital twin ecosystems substantially improve diagnostic precision through coordinated analysis of imaging, pathology, molecular biology, laboratory investigations, and clinical documentation.[16]

Deep learning algorithms automatically identify suspicious lesions across computed tomography, magnetic resonance imaging, positron emission tomography, mammography, ultrasound, and digital pathology while multimodal reasoning systems integrate these findings with genomic sequencing and longitudinal clinical information.

Real-time synchronization allows diagnostic models to update continuously as additional information becomes available, enabling more accurate disease classification, molecular characterization, staging, and individualized patient assessment.

The integration of diverse biomedical modalities within unified digital twin ecosystems supports earlier diagnosis while improving consistency, reproducibility, and multidisciplinary collaboration across precision oncology workflows.[17]

8. Predictive Clinical Intelligence

One of the defining characteristics of digital twin ecosystems is their ability to generate real-time clinical intelligence through continuous prediction of disease evolution and therapeutic outcomes. Rather than producing isolated risk estimates, these systems integrate multimodal biomedical information into adaptive computational simulations that evolve throughout patient care.[18]

Artificial intelligence continuously estimates tumor progression, metastatic dissemination, treatment response, toxicity risk, recurrence probability, progression-free survival, and overall survival while simultaneously monitoring changes in imaging, pathology, molecular biology, laboratory biomarkers, and patient physiology.

This predictive intelligence enables clinicians to anticipate future clinical events, evaluate multiple therapeutic scenarios, optimize individualized treatment strategies, and intervene proactively before adverse clinical outcomes occur. As digital twin ecosystems continue to mature, they are expected to become central components of next-generation precision oncology, supporting continuously adaptive, data-driven, and patient-centered cancer care.[19]

9. Precision Therapeutics Through Digital Twin Ecosystems

One of the most significant advantages of digital twin ecosystems is their ability to optimize personalized cancer therapy through continuous simulation of multiple treatment strategies. Unlike conventional treatment planning, which is largely based on population-derived clinical evidence, digital twin ecosystems integrate patient-specific radiological imaging, pathology, genomics, multi-omics, laboratory biomarkers, treatment history, physiological monitoring, and longitudinal clinical information to generate individualized therapeutic recommendations.[20]

Artificial intelligence evaluates expected tumor response, recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and mechanisms of therapeutic resistance across multiple therapeutic options. Virtual simulations allow clinicians to compare chemotherapy regimens, targeted therapies, endocrine therapy, immunotherapy, radiation schedules, surgical interventions, and multimodal treatment combinations before initiating clinical treatment.

Because digital twin ecosystems continuously synchronize with evolving patient data, therapeutic recommendations are dynamically updated throughout the treatment course, enabling adaptive precision medicine tailored to the changing biological characteristics of each patient's cancer.

10. Digital Twin Ecosystems in Immunotherapy

Immunotherapy has transformed modern oncology; however, accurately predicting treatment response remains one of the greatest challenges in precision medicine. Digital twin ecosystems address this complexity by integrating genomic alterations, immunomic profiles, transcriptomics, radiological imaging, digital pathology, cytokine signaling, laboratory biomarkers, and clinical outcomes into comprehensive computational immune models.[21]

Artificial intelligence continuously evaluates tumor-infiltrating lymphocytes, immune checkpoint expression, stromal remodeling, inflammatory pathways, and spatial immune-cell organization to simulate interactions between malignant cells and the immune system. These virtual immune ecosystems estimate responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies.

Continuous learning from treatment outcomes enables these computational models to refine therapeutic recommendations over time while supporting increasingly individualized immunotherapeutic strategies.

11. Adaptive Radiation Therapy and Surgical Intelligence

Radiation oncology and surgical oncology benefit substantially from the real-time adaptability provided by digital twin ecosystems. During radiation therapy, sequential imaging updates virtual patient models throughout treatment, allowing artificial intelligence to modify tumor contours, estimate radiation sensitivity, optimize dose distribution, and adapt treatment plans according to evolving anatomical and biological characteristics.[22]

These adaptive radiation workflows improve tumor targeting while minimizing radiation exposure to surrounding healthy tissues, thereby enhancing treatment efficacy and reducing toxicity.

Within surgical oncology, three-dimensional digital twins generated from high-resolution imaging provide detailed visualization of tumor location, vascular anatomy, adjacent organs, and critical neurovascular structures. Artificial intelligence further predicts surgical complexity, estimates resection margins, evaluates postoperative complications, and simulates multiple operative strategies before surgery, improving precision and patient safety.

12. Drug Discovery, Clinical Trials, and Learning Health Systems

Digital twin ecosystems extend beyond direct patient care into oncology research, pharmaceutical development, and continuously learning healthcare systems. Artificial intelligence integrates molecular biology, systems pharmacology, genomics, proteomics, metabolomics, clinical outcomes, and virtual patient simulations to predict drug efficacy, toxicity, resistance mechanisms, and optimal dosing strategies before laboratory or clinical evaluation.[23]

Generative AI further accelerates drug discovery through molecular design, protein interaction modeling, target identification, and synthetic biomedical data generation. Within clinical trials, digital twin ecosystems improve patient recruitment, eligibility assessment, adaptive trial design, molecular stratification, and real-time outcome monitoring.

Learning health systems continuously incorporate new clinical evidence from routine practice, enabling digital twin ecosystems to improve prediction accuracy and therapeutic recommendations across expanding patient populations.

13. Clinical Decision Support and Intelligent Oncology Workflows

Modern oncology requires continuous interpretation of enormous quantities of clinical information generated across diagnosis, treatment, follow-up, and survivorship. Digital twin ecosystems function as intelligent clinical decision-support platforms by integrating radiological imaging, pathology reports, genomic sequencing, laboratory investigations, wearable sensor data, medication history, and longitudinal patient records into unified computational environments.[24]

Interactive dashboards provide clinicians with individualized diagnostic summaries, therapeutic recommendations, toxicity estimates, recurrence predictions, and survival probabilities while enabling comparison of multiple treatment scenarios.

Artificial intelligence also automates documentation, summarizes multidisciplinary tumor board discussions, retrieves relevant clinical guidelines, identifies eligible clinical trials, and continuously monitors patient progress, thereby reducing administrative workload while improving multidisciplinary collaboration and healthcare efficiency.

14. Explainable Artificial Intelligence, Cybersecurity, and Ethical Governance

For digital twin ecosystems to achieve widespread clinical implementation, clinicians must trust the computational recommendations generated by these intelligent systems. Explainable artificial intelligence (XAI) enables interpretation of model predictions using attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, and counterfactual reasoning that identify the biological variables contributing most strongly to clinical decisions.[25]

Several important challenges remain. Large-scale digital twin ecosystems require robust interoperability among imaging platforms, pathology laboratories, genomic sequencing facilities, wearable technologies, hospital information systems, and cloud infrastructure. Additional concerns include algorithmic bias, patient privacy, cybersecurity, informed consent, regulatory approval, liability, and equitable access to advanced computational healthcare technologies.

Addressing these challenges will require transparent governance frameworks, standardized interoperability standards, secure computational infrastructure, prospective clinical validation, and multidisciplinary collaboration among clinicians, engineers, computer scientists, regulators, and healthcare organizations.

15. Future Perspectives

Future digital twin ecosystems are expected to evolve into fully integrated intelligent oncology platforms capable of continuously coordinating radiology, pathology, genomics, laboratory medicine, surgery, radiation oncology, pharmacy, wearable technologies, and electronic health records within unified computational environments.[26]

Foundation models, multimodal large language models, agentic artificial intelligence, reinforcement learning, federated learning, quantum computing, spatial multi-omics, liquid biopsy, cloud-native healthcare infrastructure, and Internet of Medical Things (IoMT) technologies will substantially strengthen predictive capabilities while improving scalability across healthcare systems.

These intelligent ecosystems may eventually function as continuously learning virtual oncology networks capable of providing personalized clinical intelligence, adaptive therapeutic planning, automated workflow coordination, and evidence-based decision support throughout the entire cancer care continuum.

16. Discussion

Digital twin ecosystems represent the next evolutionary stage of computational oncology by extending virtual patient technology into continuously connected intelligent healthcare environments. Rather than functioning as isolated computational models, these ecosystems integrate multimodal biomedical information, hospital information systems, artificial intelligence, cloud computing, and real-time clinical workflows into adaptive precision oncology platforms.[27]

Applications spanning cancer diagnosis, therapeutic optimization, immunotherapy, radiation oncology, surgical planning, drug discovery, clinical trial management, and intelligent clinical decision support demonstrate the transformative potential of digital twin ecosystems for improving patient-centered cancer care.

Nevertheless, successful implementation requires rigorous prospective validation, transparent governance, explainable artificial intelligence, standardized interoperability, secure computational infrastructure, and continuous physician oversight to ensure safe, reliable, and equitable deployment across diverse healthcare environments.[28]

17. Conclusion

Digital twin ecosystems are redefining personalized oncology by connecting virtual patients with real-time clinical intelligence through continuous integration of radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical information into adaptive computational environments.[29]

Artificial intelligence enables these ecosystems to continuously synchronize with evolving patient conditions, simulate disease progression, optimize therapeutic strategies, predict clinical outcomes, and support multidisciplinary decision-making throughout diagnosis, treatment, follow-up, and survivorship. As foundation models, multimodal learning, agentic AI, digital twins, federated learning, cloud computing, and computational systems biology continue to mature, digital twin ecosystems are expected to become fundamental components of next-generation precision oncology.

Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration will accelerate responsible implementation of these intelligent healthcare ecosystems, ultimately transforming cancer care into a predictive, preventive, adaptive, and highly personalized model of precision medicine.[30]

18. References

1.Synthia, F. et al. (2020) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

3.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

4.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

5.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

6.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

7.Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

8.Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

9.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.

10.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

11.Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.

12.Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.

13.Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.

14.Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

15.Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

16.Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

17.Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

18.Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.

19.Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.

20.Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

21.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

22.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

23.Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.

24.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

25.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and

Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

26.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

27.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

28.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

29.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

30.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7